Latest Asx Market News

iCandy Interactive is exploring a US listing for its subsidiary Lemon Sky Studios to unlock shareholder value, while facing a likely ASX delisting due to audit delays. The company also plans a capital raise to support these initiatives.

Kjerulf David Hastings Ainsworth has initiated a second proportional takeover bid for 5.5% of Ainsworth Game Technology shares at $1.30 each, offering shareholders a significant premium and cash certainty. The move underscores Ainsworth’s belief that AGI remains undervalued amid a low likelihood of competing bids.

Sports Entertainment Group Limited has announced a significant on-market share buy-back program, aiming to repurchase up to 10% of its shares over the next year starting March 2026. The move reflects the board's confidence in the company's underlying value amid current market pricing.

Apiam Animal Health has officially become a wholly owned subsidiary of Adamantem Capital's entities following a scheme of arrangement, with shareholders receiving a special dividend and a mix of cash and shares. The company will soon be delisted from the ASX.

Global X Management (AUS) Limited has announced estimated distributions for three ETFs listed on the ASX AQUA Market for the period ending 28 February 2026, providing key dates and dividend reinvestment plan eligibility.

Macmahon Holdings has reported a robust first half of FY26, delivering double-digit growth in revenue and earnings alongside a significant dividend increase and reaffirmed full-year guidance.

ResMed Inc has updated the foreign exchange rate for its upcoming dividend payment to Australian CDI holders, impacting the Australian dollar amount payable per share. The dividend remains unfranked and subject to US withholding tax, with a reduced rate available under the US-Australia tax treaty.

WIN Metals Ltd has launched a prospectus offering up to 78.57 million free attaching options to recent placement participants and its Executive Chairman, aiming to remove trading restrictions and enable market liquidity. The offer follows a $5.5 million capital raise and comes amid ongoing litigation risks.

PYC Therapeutics has launched a A$653 million capital raising to fund the clinical advancement of four RNA-based drug candidates targeting genetic diseases with significant unmet needs. The raise extends the company’s cash runway to 2030, supporting key clinical milestones and a transition to commercialisation.

Global X Management (AUS) Limited has released updated estimated distribution amounts for over 30 ETFs listed on the ASX AQUA Market for the period ending 31 December 2025, alongside key dates for investors to note.

Opthea Limited has announced a strategic pivot to develop OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women, aiming for ASX reinstatement in 2026. The company leverages strong intellectual property and cash reserves to pursue orphan drug designation and clinical development.

Magellan Asset Management has launched the Magellan Infrastructure Fund (Currency Hedged), an actively managed ETF trading on the ASX under ticker MICH, targeting global listed infrastructure with currency hedging and ESG integration.